All In Biotech

Drug Trial Radar · NCT05337878

A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants

A Randomized Double-blind, Placebo-controlled, Non-confirmatory Study to Assess Safety, Tolerability, PK, and PD of Single Ascending and Multiple Doses of ISIS 681257 in Healthy Japanese Participants

Last checked: Nov 19, 2026Latest source record: Apr 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Oct 15, 2018

Primary completion

Dec 18, 2019

Study completion Dec 18, 2019

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Apr 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple subcutaneous (SC) doses of Pelacarsen (ISIS 681257) in healthy Japanese participants.

Conditions

  • Healthy Participants

Interventions

  • PlaceboDrug

    Pelacarsen-matching placebo administered by SC injection.

  • PelacarsenDrug

    Pelacarsen administered by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAD: Percentage of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Evaluation ParametersTime frame: Up to Day 90
  2. SAD: Percentage of Participants With Adverse EventsTime frame: Up to Day 90
  3. SAD: Percentage of Participants With Serious Adverse EventsTime frame: Up to Day 90
  4. MAD: Percentage of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Evaluation ParametersTime frame: Up to Day 204
  5. MAD: Percentage of Participants With Adverse EventsTime frame: Up to Day 204
  6. MAD: Percentage of Participants With Serious Adverse EventsTime frame: Up to Day 204

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel International

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.